The DOI matches its Crossref record; 152 of the 153 references it cites were found in a registry or an index; 64 of the 121 sources its claims cite were checked for support.
The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications
Open accessAbstract
GLP-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes (T2D) and obesity, with robust evidence for cardiovascular and renal benefits. Nevertheless, GLP-1RA therapy is associated with a pattern of adverse events affecting their safety and tolerability. Here, we delineate mechanisms potentially leading to adverse responses to GLP-1RAs, describe the impact of side effects on treatment persistence, discuss potential mitigation strategies, and identify areas requiring further studies. Concerns that GLP-1RAs raise the risk for acute pancreatitis and pancreatic cancer have been dispelled by long-term clinical trials. However, GLP-1RAs may confer an increased risk for thyroid cancer. Sight-threatening eye complications resulting from rapid reductions in glycemia may be avoided by retinal screening and ophthalmologic treatment before GLP-1RA initiation. The slowing of gastric emptying with GLP-1RA treatment increases the propensity for retained gastric contents, which could increase the risk of aspiration during upper gastrointestinal endoscopy or general anesthesia. These risks may, however, be elevated in individuals with long-standing T2D even in the absence of GLP-1RA treatment. Improved pharmacovigilance and a more standardized, quantitative assessment of adverse events in clinical trials, particularly in the assessment of gastrointestinal symptoms, would facilitate definition of the benefit-risk relationship for individual medications.
Overview
CoChat Summary
## TL;DR
This is a narrative review of adverse effects associated with GLP-1 receptor agonists (and tirzepatide), emphasizing gastrointestinal tolerability, thyroid and eye safety, and risks in specific populations. The paper argues that several feared harms (notably pancreatitis and pancreatic cancer) have been largely dispelled by longer-term trials, while GI side effects, retained gastric contents, and possible thyroid/ocular risks remain clinically important.
## Key findings
- In a systematic review of 39 randomized controlled trials in people without diabetes, GLP-1RAs increased risk of nausea, vomiting, diarrhea, and constipation versus placebo; for newer therapies, nausea risk versus placebo was semaglutide RR 2.95 (95% CI 2.61–3.32), tirzepatide RR 2.90 (95% CI 2–4.19), and orforglipron RR 4.77 (95% CI 2.02–11.31).
- In another systematic review of 38 phase III/IV placebo-controlled trials in T2D, nausea occurred in 19.3% with active treatment versus 6.5% with placebo, and vomiting in 7.6% versus 2% with placebo; 6.5% of GLP-1RA users discontinued due to adverse events versus 3.6% on placebo.
- GLP-1RAs were associated with increased retained gastric contents: one study reported 56% in GLP-1RA users versus 19% in non-users; three systematic reviews found increased odds of premature endoscopy termination from retained gastric contents (OR 4.5, 5.6, and 13.9), but no review found an increased risk of aspiration pneumonia.
- The review states that concerns about acute pancreatitis and pancreatic cancer have been “dispelled” by long-term trials, but that GLP-1RAs may confer an increased risk for thyroid cancer and that retinopathy complications can occur with rapid glycemic improvement, especially in people with pre-existing advanced retinopathy.
## Methods
- Narrative review of GLP-1 receptor agonist safety, covering GI, psychiatric, ocular, thyroid, biliary/pancreatic, and population-specific adverse effects.
- Synthesizes evidence from systematic reviews, randomized controlled trials, cohort studies, case-control studies, and pharmacovigilance reports, with examples drawn from T2D, obesity, cirrhosis, CKD, older adults, pregnancy, and younger individuals.
- Main analysis is qualitative synthesis of published studies, reporting relative risks, odds ratios, hazard ratios, and event rates where available; no new primary data collection is described.
## Limitations
- The paper itself notes that surprisingly little research has comprehensively assessed even common GI adverse events, and that adverse-event documentation is suboptimal, making differences between compounds/preparations hard to appreciate.
- It also states that many safety signals rely on pharmacovigilance databases and observational studies, which are prone to reporting bias and confounding; this is explicitly stated in the paper.
- Evident from the text: this is a review, so conclusions depend on the quality and heterogeneity of underlying studies; several sections explicitly say larger, prospective, or dedicated studies are needed to confirm associations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
50 Valid · 3 Not valid · 34 Not checked · 11 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“a substantial proportion (>50%) of the participants did not report any GI adverse events”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > GI side effects
What the sources say
- Disputedcites [21] sourceExperimental — accuracy not yet measured
The Results > Safety table reports gastrointestinal disorders in 28 of 60, 41 of 60, 44 of 62, and 20 of 59 participants across the four groups. That totals 133 of 241 participants (55%) reporting a GI adverse event, leaving fewer than 50% without one across the trial. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“most human medullary thyroid carcinomas and hyperplastic C cells express GLP-1R (75, 77) (Figure 2).”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > Thyroid carcinomas
What the sources say
- Supportedcites [75] source
The Results (Table 2; page unavailable) show GLP-1R immunoreactivity in 11 of 12 medullary thyroid carcinomas and all nine C-cell hyperplasia specimens. The Discussion also describes expression as common in both, while noting that the proportion of positive cells varies within lesions. (LLM, conf=0.93)
- Disputedcites [77] sourceExperimental — accuracy not yet measured
The Discussion reports GLP-1R expression in 28% of medullary thyroid carcinomas examined, contrary to the claim that most express it. It also says many calcitonin-positive C cells were GLP-1R-negative; the copy does not establish expression in most hyperplastic C cells. No page number is provided in our copy. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“GI adverse events not infrequently lead to discontinuation of drug treatment, both in randomized clinical trials (16, 17) and in real-world practice (18, 19).”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > GI side effects
What the sources say
- Supportedcites [16] source
This source is cited for the randomized-clinical-trial portion of the sentence, not the separately cited real-world portion. The Discussion explicitly refers to treatment discontinuation due to GI adverse events, and the Results (Safety and tolerability outcomes; page unavailable) report that 6.5% of participants receiving incretin mimetics discontinued because of adverse events. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [17] source
- Not checked — no full text of the sourcecites [18] source
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
For the real-world-practice portion attributed to this paper, the Discussion (Study Objectives and Main Results; page unavailable) reports that 5.0% of UK patients and 12.3% of German patients received no second GLP-1 prescription, and suggests this may be due to common gastrointestinal adverse events. It does not establish that those events caused the discontinuations. The randomized-trial portion is cited to other sources, not this paper. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > Abstract
What the sources say
- Not checked — no full text of the sourcecites [8] source
- Not checked — no full text of the sourcecites [9] source
- Not checked — no full text of the sourcecites [10] source
- Not checked — no full text of the sourcecites [11] source
- Supportedcites [12] source
The paper reports GLP-1R expression in pancreatic islet β-cells (Concluding remarks for GLP-1R expression and function in the pancreas, p. 20), throughout the CNS (Where does brain GLP-1 originate from?, p. 21), and across the GI tract (GLP-1R expression in the gastrointestinal tract, p. 40). It describes expression in only a subset of renal blood vessels (p. 37) and fewer than 1% of cells in the human retinal ganglion cell layer (p. 48), consistent with the claim's less-prominent qualification. (LLM, conf=0.86)
- Supportedcites [13] source
The Results (GLP-1R expression in normal human eyes) found receptor-positive cells in less than 1% of ganglion cell layer cells and weaker staining in the monkey renal cortex. This supports the cited paper’s contribution to the statement that expression in the eyes, and to a lesser extent the kidney, is limited; it does not establish the sentence’s separate comparison with brain expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“6.5% of those using a GLP-1RA discontinued it due to adverse events versus 3.6% of those on placebo (16)”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > GI side effects
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Results (Safety and tolerability outcomes, ‘Treatment discontinuation’) report 6.5% discontinuation due to adverse events in the active-treatment group, but 2.9% in the placebo group—not 3.6%. The analysis covers incretin mimetics, including tirzepatide, rather than GLP-1 receptor agonists alone. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 32 with their cited sources checked
Create a free account to see all 98 claims and to verify the 9 references still open.
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
- Probably not a substantial claim. 6
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The first trial reporting detailed results on adjudicated cases of suspected acute pancreatitis was the LEADER trial comparing liraglutide and placebo in patients with T2D (18 cases in 4668 participants randomized to liraglutide treatment vs. 23 in 4672 with placebo treatment) (67).”
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Subcutaneous semaglutide treatment led to an increased number of retinopathy complications in the SUS-TAIN-6 cardiovascular outcomes trial (81).”
Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“Moreover, in a recent large cardiovascular outcomes trial (SURPASS-CVOT), numerically higher proportions of participants taking tirzepatide (15 mg weekly) reported nausea, vomiting, and diarrhea compared with those taking the selective GLP-1RA dulaglutide (1.5 mg weekly) (25).”
InfluentialNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“This class of drugs is now used widely, with beneficial GLP-1R–mediated effects on body weight and glycemic control, as well as their cardio-renal complications (7, 14).”
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Indeed, GLP-1R agonism slows gastric emptying (51, 52) and suppresses small intestinal motility (53).”
Cited by
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 14
“81 Nausea, early satiety, bloating, and mild constipation are common during initiation and dose escalation, likely reflecting delayed gastric emptying.”
Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit?
Walker, T., Sherriff, S., & Browne, J. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70246 · Cited by 2
“At the same time, reports of adverse effects and concerns about long-term safety continue to emerge [18].”
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Metadata
- Authors
- Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A.
- Affiliations
- Royal Adelaide Hospital (AU)
- University of Newcastle Australia (AU)
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Journal of Clinical Investigation
- Published
- 2026-02-16
- Volume
- 136
- Issue
- 4
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12904723
- OpenAlex
- W7128962556
- Cited by
- 40
- References
- 152
- Citations by year
- 2026: 40
- FWCI
- 42.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Brown University
- Australian Diabetes Society
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, drug safety, adverse events, type 2 diabetes, obesity, acute pancreatitis, pancreatic cancer, thyroid cancer, retinal complications, gastric emptying, aspiration risk, treatment persistence, pharmacovigilance, risk-benefit assessment, gastrointestinal symptoms
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Gastric Emptying, Humans, Hypoglycemic Agents, Obesity, Pancreatic Neoplasms, Pancreatitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. https://app.cochat.ai/papers/10.1172/jci194740
- The paper
- Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026). The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. Journal of Clinical Investigation. https://doi.org/10.1172/jci194740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.